Compile Data Set for Download or QSAR
maximum 50k data
Found 854 of ic50 for UniProtKB: P46098
Target5-hydroxytryptamine receptor 3A/3B/3C/3D/3E(Homo sapiens (Human))
Universit£

Curated by ChEMBL
LigandPNGBDBM50058283(6-(4-Benzyl-piperazin-1-yl)-pyrido[3,2-e]pyrrolo[1...)
Affinity DataIC50:  0.000813nMAssay Description:Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligandMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
Target5-hydroxytryptamine receptor 3A/3B/3C/3D/3E(Homo sapiens (Human))
Universit£

Curated by ChEMBL
LigandPNGBDBM50408165(CHEMBL299231)
Affinity DataIC50:  0.00398nMAssay Description:Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligandMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
Target5-hydroxytryptamine receptor 3A/3B/3C/3D/3E(Homo sapiens (Human))
Universit£

Curated by ChEMBL
LigandPNGBDBM50408166(CHEMBL416662)
Affinity DataIC50:  0.0813nMAssay Description:Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligandMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
H. Lundbeck

Curated by ChEMBL
LigandPNGBDBM85330(CAS_68647 | NSC_68647 | ONDANSETRON | Ondansetron ...)
Affinity DataIC50:  0.0900nMAssay Description:Antagonist activity at human 5HT3A receptor expressed in xenopus oocytes assessed as inhibition of 5HT-induced effect by electrophysiological methodMore data for this Ligand-Target Pair
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
H. Lundbeck

Curated by ChEMBL
LigandPNGBDBM221600(US9303045, 87 | US9695195, 87)
Affinity DataIC50:  0.180nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
H. Lundbeck

Curated by ChEMBL
LigandPNGBDBM221600(US9303045, 87 | US9695195, 87)
Affinity DataIC50:  0.180nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
H. Lundbeck

Curated by ChEMBL
LigandPNGBDBM221544(US9303045, 30 | US9695195, 30)
Affinity DataIC50:  0.200nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
H. Lundbeck

Curated by ChEMBL
LigandPNGBDBM221544(US9303045, 30 | US9695195, 30)
Affinity DataIC50:  0.200nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
H. Lundbeck

Curated by ChEMBL
LigandPNGBDBM221601(US9303045, 88 | US9695195, 88)
Affinity DataIC50:  0.220nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
H. Lundbeck

Curated by ChEMBL
LigandPNGBDBM221601(US9303045, 88 | US9695195, 88)
Affinity DataIC50:  0.220nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
H. Lundbeck

Curated by ChEMBL
LigandPNGBDBM221592(US9303045, 127 | US9303045, 79 | US9695195, 127)
Affinity DataIC50:  0.220nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
H. Lundbeck

Curated by ChEMBL
LigandPNGBDBM221592(US9303045, 127 | US9303045, 79 | US9695195, 127)
Affinity DataIC50:  0.220nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
H. Lundbeck

Curated by ChEMBL
LigandPNGBDBM221622(US9303045, 113 | US9695195, 113)
Affinity DataIC50:  0.230nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
H. Lundbeck

Curated by ChEMBL
LigandPNGBDBM221622(US9303045, 113 | US9695195, 113)
Affinity DataIC50:  0.230nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
H. Lundbeck

Curated by ChEMBL
LigandPNGBDBM221572(US9303045, 58 | US9695195, 58)
Affinity DataIC50:  0.240nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
H. Lundbeck

Curated by ChEMBL
LigandPNGBDBM221572(US9303045, 58 | US9695195, 58)
Affinity DataIC50:  0.240nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
H. Lundbeck

Curated by ChEMBL
LigandPNGBDBM221624(US9303045, 117 | US9303045, 123 | US9695195, 123)
Affinity DataIC50:  0.280nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
H. Lundbeck

Curated by ChEMBL
LigandPNGBDBM221624(US9303045, 117 | US9303045, 123 | US9695195, 123)
Affinity DataIC50:  0.280nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A/3B/3C/3D/3E(Homo sapiens (Human))
Universit£

Curated by ChEMBL
LigandPNGBDBM50408162(CHEMBL299634)
Affinity DataIC50:  0.288nMAssay Description:Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligandMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
H. Lundbeck

Curated by ChEMBL
LigandPNGBDBM221610(US9303045, 99 | US9695195, 99)
Affinity DataIC50:  0.290nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
H. Lundbeck

Curated by ChEMBL
LigandPNGBDBM221610(US9303045, 99 | US9695195, 99)
Affinity DataIC50:  0.290nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
H. Lundbeck

Curated by ChEMBL
LigandPNGBDBM221654(US9303045, 159 | US9695195, 159)
Affinity DataIC50:  0.298nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
H. Lundbeck

Curated by ChEMBL
LigandPNGBDBM221654(US9303045, 159 | US9695195, 159)
Affinity DataIC50:  0.300nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
H. Lundbeck

Curated by ChEMBL
LigandPNGBDBM221651(US9303045, 154 | US9695195, 154)
Affinity DataIC50:  0.328nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
H. Lundbeck

Curated by ChEMBL
LigandPNGBDBM221651(US9303045, 154 | US9695195, 154)
Affinity DataIC50:  0.330nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
H. Lundbeck

Curated by ChEMBL
LigandPNGBDBM221561(US9303045, 47 | US9695195, 47)
Affinity DataIC50:  0.330nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
H. Lundbeck

Curated by ChEMBL
LigandPNGBDBM221561(US9303045, 47 | US9695195, 47)
Affinity DataIC50:  0.330nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A/3B/3C/3D/3E(Homo sapiens (Human))
Universit£

Curated by ChEMBL
LigandPNGBDBM50408167(CHEMBL53416)
Affinity DataIC50:  0.355nMAssay Description:Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligandMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
H. Lundbeck

Curated by ChEMBL
LigandPNGBDBM221624(US9303045, 117 | US9303045, 123 | US9695195, 123)
Affinity DataIC50:  0.390nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
H. Lundbeck

Curated by ChEMBL
LigandPNGBDBM221627(US9303045, 120 | US9695195, 120)
Affinity DataIC50:  0.390nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
H. Lundbeck

Curated by ChEMBL
LigandPNGBDBM221624(US9303045, 117 | US9303045, 123 | US9695195, 123)
Affinity DataIC50:  0.390nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
H. Lundbeck

Curated by ChEMBL
LigandPNGBDBM221627(US9303045, 120 | US9695195, 120)
Affinity DataIC50:  0.390nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
H. Lundbeck

Curated by ChEMBL
LigandPNGBDBM221648(US9303045, 147 | US9695195, 147)
Affinity DataIC50:  0.400nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
H. Lundbeck

Curated by ChEMBL
LigandPNGBDBM221626(US9303045, 119 | US9695195, 148)
Affinity DataIC50:  0.400nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
H. Lundbeck

Curated by ChEMBL
LigandPNGBDBM221535(US9303045, 20 | US9695195, 20)
Affinity DataIC50:  0.400nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
H. Lundbeck

Curated by ChEMBL
LigandPNGBDBM221622(US9303045, 113 | US9695195, 113)
Affinity DataIC50:  0.400nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
H. Lundbeck

Curated by ChEMBL
LigandPNGBDBM221648(US9303045, 147 | US9695195, 147)
Affinity DataIC50:  0.400nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
H. Lundbeck

Curated by ChEMBL
LigandPNGBDBM221649(US9303045, 148)
Affinity DataIC50:  0.400nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
H. Lundbeck

Curated by ChEMBL
LigandPNGBDBM221535(US9303045, 20 | US9695195, 20)
Affinity DataIC50:  0.400nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
H. Lundbeck

Curated by ChEMBL
LigandPNGBDBM221626(US9303045, 119 | US9695195, 148)
Affinity DataIC50:  0.400nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
H. Lundbeck

Curated by ChEMBL
LigandPNGBDBM221679(US9303045, 21)
Affinity DataIC50:  0.400nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
H. Lundbeck

Curated by ChEMBL
LigandPNGBDBM221626(US9303045, 119 | US9695195, 148)
Affinity DataIC50:  0.400nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
H. Lundbeck

Curated by ChEMBL
LigandPNGBDBM221592(US9303045, 127 | US9303045, 79 | US9695195, 127)
Affinity DataIC50:  0.410nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
H. Lundbeck

Curated by ChEMBL
LigandPNGBDBM221592(US9303045, 127 | US9303045, 79 | US9695195, 127)
Affinity DataIC50:  0.410nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
H. Lundbeck

Curated by ChEMBL
LigandPNGBDBM221644(US9303045, 143 | US9695195, 143)
Affinity DataIC50:  0.415nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
H. Lundbeck

Curated by ChEMBL
LigandPNGBDBM221644(US9303045, 143 | US9695195, 143)
Affinity DataIC50:  0.420nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
H. Lundbeck

Curated by ChEMBL
LigandPNGBDBM221587(US9303045, 74 | US9695195, 74)
Affinity DataIC50:  0.420nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
H. Lundbeck

Curated by ChEMBL
LigandPNGBDBM221587(US9303045, 74 | US9695195, 74)
Affinity DataIC50:  0.420nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
H. Lundbeck

Curated by ChEMBL
LigandPNGBDBM221574(US9303045, 60 | US9695195, 60)
Affinity DataIC50:  0.440nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
H. Lundbeck

Curated by ChEMBL
LigandPNGBDBM221574(US9303045, 60 | US9695195, 60)
Affinity DataIC50:  0.440nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 854 total ) | Next | Last >>
Jump to: